Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
Authors
Keywords
-
Journal
Drug Design Development and Therapy
Volume Volume 14, Issue -, Pages 3731-3746
Publisher
Informa UK Limited
Online
2020-09-15
DOI
10.2147/dddt.s272355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Astragaloside IV enhances GATA-4 mediated myocardial protection effect in Hypoxia/Reoxygenation injured H9c2 cells
- (2020) Jing-Jing Yang et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Astragaloside IV attenuates chronic intermittent hypoxia‐induced myocardial injury by modulating Ca 2+ homeostasis
- (2020) Shan Jiang et al. CELL BIOCHEMISTRY AND FUNCTION
- Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels
- (2020) Paolo Severino et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a
- (2020) Yang Wu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM
- (2020) Zhongyuan Wang et al. BIOMEDICINE & PHARMACOTHERAPY
- Anti-tumor effects and mechanisms of Astragalus membranaceus (AM) and its specific immunopotentiation: Status and prospect
- (2020) Shanshan Li et al. JOURNAL OF ETHNOPHARMACOLOGY
- Angiogenic function of astragaloside IV in rats with myocardial infarction occurs via the PKD1‑HDAC5‑VEGF pathway
- (2019) Lei Yang et al. Experimental and Therapeutic Medicine
- Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway
- (2019) Yan-Bo Sui et al. PHARMACEUTICAL BIOLOGY
- Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application
- (2019) Dong Xu et al. MOLECULES
- Astragaloside IV promotes the eNOS/NO/cGMP pathway and improves left ventricular diastolic function in rats with metabolic syndrome
- (2019) Xin Lin et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Astragaloside IV Regulates the PI3K/Akt/HO-1 Signaling Pathway and Inhibits H9c2 Cardiomyocyte Injury Induced by Hypoxia–Reoxygenation
- (2019) Ping Yang et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway
- (2019) Songyi Cheng et al. LIFE SCIENCES
- Astragaloside IV Exerts a Myocardial Protective Effect against Cardiac Hypertrophy in Rats, Partially via Activating the Nrf2/HO-1 Signaling Pathway
- (2019) Pei Nie et al. Oxidative Medicine and Cellular Longevity
- Astragaloside IV Attenuates Myocardial Ischemia-Reperfusion Injury from Oxidative Stress by Regulating Succinate, Lysophospholipid Metabolism, and ROS Scavenging System
- (2019) Miaomiao Jiang et al. Oxidative Medicine and Cellular Longevity
- Ononin, sec-O-β-d-glucosylhamaudol and astragaloside I: antiviral lead compounds identified via high throughput screening and biological validation from traditional Chinese medicine Zhongjing formulary
- (2019) Yunru Yu et al. PHARMACOLOGICAL RESEARCH
- Astragaloside IV protects cardiomyocytes from hypoxia-induced injury by down-regulation of lncRNA GAS5
- (2019) Jian Du et al. BIOMEDICINE & PHARMACOTHERAPY
- Nutritional preconditioning induced by astragaloside Ⅳ on isolated hearts and cardiomyocytes against myocardial ischemia injury via improving Bcl-2-mediated mitochondrial function
- (2019) Yong Luo et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and Calpain-1 activation
- (2019) Qu Nie et al. LIFE SCIENCES
- Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism
- (2019) Zhen Zhang et al. Molecular Medicine Reports
- Astragaloside IV attenuates gestational diabetes mellitus via targeting NLRP3 inflammasome in genetic mice
- (2019) Ruixue Zhang et al. Reproductive Biology and Endocrinology
- Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway
- (2019) Yanchun Wei et al. JOURNAL OF ETHNOPHARMACOLOGY
- Astragaloside-IV protects H9C2(2-1) cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway
- (2019) Yaobin Zhu et al. Artificial Cells Nanomedicine and Biotechnology
- Astragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis
- (2019) Zhuang Zhuang et al. Frontiers in Pharmacology
- Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways
- (2018) Bo Yin et al. ACTA PHARMACOLOGICA SINICA
- Astragaloside IV protects against the pathological cardiac hypertrophy in mice
- (2018) Zhen-hu Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Astragalosides increase the cardiac diastolic function and regulate the “Calcium sensing receptor-protein kinase C-protein phosphatase 1” pathway in rats with heart failure
- (2018) Yansu Ji et al. BIOMEDICINE & PHARMACOTHERAPY
- Astragaloside IV inhibits ventricular remodeling and improves fatty acid utilization in rats with chronic heart failure
- (2018) Bin Tang et al. BIOSCIENCE REPORTS
- Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway
- (2018) Ruijuan Zhou et al. BMC Complementary and Alternative Medicine
- Preventive effects of astragaloside IV and its active sapogenin cycloastragenol on cardiac fibrosis of mice by inhibiting the NLRP3 inflammasome
- (2018) Yu Wan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Mechanisms of physiological and pathological cardiac hypertrophy
- (2018) Michinari Nakamura et al. Nature Reviews Cardiology
- The Role of Saikosaponins in Therapeutic Strategies for Age-Related Diseases
- (2018) Byeong Mo Kim Oxidative Medicine and Cellular Longevity
- MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress.
- (2018) Jie Yuan et al. Theranostics
- Astragaloside IV Protects Rat Cardiomyocytes from Hypoxia-Induced Injury by Down-Regulation of miR-23a and miR-92a
- (2018) Licheng Gong et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway
- (2018) Bin Leng et al. LIFE SCIENCES
- Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102)
- (2018) Lin-Sen Qing et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Calcium Sensing Receptor-Related Pathway Contributes to Cardiac Injury and the Mechanism of Astragaloside IV on Cardioprotection
- (2018) Meili Lu et al. Frontiers in Pharmacology
- Astragalus Granule Prevents Ca2+ Current Remodeling in Heart Failure by the Downregulation of CaMKII
- (2017) Sinai Li et al. Evidence-based Complementary and Alternative Medicine
- Sarcoplasmic reticulum Ca 2+ , Mg 2+ , K + , and Cl − concentrations adjust quickly as heart rate changes
- (2017) Claudio Berti et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Inhibition of cardiotrophin-1 overexpression is involved in the anti-fibrotic effect of Astrogaloside IV
- (2017) Guizhi Jia et al. Molecular Medicine Reports
- Astragaloside IV inhibits isoprenaline-induced cardiac fibrosis by targeting the reactive oxygen species/mitogen-activated protein kinase signaling axis
- (2017) Hongliang Dai et al. Molecular Medicine Reports
- Astragaloside attenuates myocardial injury in a rat model of acute myocardial infarction by upregulating hypoxia inducible factor-1α and Notch1/Jagged1 signaling
- (2017) Junmin Yu et al. Molecular Medicine Reports
- AstragalosideⅣ against cardiac fibrosis by inhibiting TRPM7 channel
- (2017) Jun Lu et al. PHYTOMEDICINE
- The effect of different proportions of astragaloside and curcumin on DM model of mice
- (2017) Mingsan Miao et al. SAUDI PHARMACEUTICAL JOURNAL
- Tanshinone IIA and Astragaloside�IV promote the angiogenesis of mesenchymal stem cell-derived endothelial cell-like cells via upregulation of Cx37, Cx40 and Cx43
- (2017) Zhe Li et al. Experimental and Therapeutic Medicine
- Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota
- (2017) Ming Lyu et al. Frontiers in Microbiology
- Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy
- (2017) Ke-Qiong Deng et al. CIRCULATION
- Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein
- (2016) Huang Huang et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
- (2016) Muhammad Shahzad et al. CURRENT DRUG TARGETS
- Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways
- (2016) Chonghua Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Ion Channel Macromolecular Complexes in Cardiomyocytes: Roles in Sudden Cardiac Death
- (2015) H. Abriel et al. CIRCULATION RESEARCH
- Astragaloside IV attenuates apoptosis of hypertrophic cardiomyocyte through inhibiting oxidative stress and calpain-1 activation
- (2015) Meng Mei et al. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
- Effects of Astragaloside IV on the SDF-1/CXCR4 Expression in Atherosclerosis of apoE−/−Mice Induced by Hyperlipaemia
- (2015) Hewei Qin et al. Evidence-based Complementary and Alternative Medicine
- Biological Active Ingredients of Traditional Chinese Herb Astragalus membranaceus on Treatment of Diabetes: A Systematic Review
- (2015) Zhang Kai et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction
- (2015) JUN-MIN YU et al. Molecular Medicine Reports
- Cardioprotective and nonprotective regimens of chronic hypoxia diversely affect the myocardial antioxidant systems
- (2015) Dita Kasparova et al. PHYSIOLOGICAL GENOMICS
- Astragaloside IV Attenuates Injury Caused by Myocardial Ischemia/Reperfusion in Rats via Regulation of Toll-Like Receptor 4/Nuclear Factor-κB Signaling Pathway
- (2015) Meili Lu et al. PHYTOTHERAPY RESEARCH
- Astragaloside IV Protects against Isoproterenol-Induced Cardiac Hypertrophy by Regulating NF-κB/PGC-1α Signaling Mediated Energy Biosynthesis
- (2015) Suping Zhang et al. PLoS One
- Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats
- (2014) Jianguo Chen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A Review of Recent Research Progress on the Astragalus Genus
- (2014) Xiaoxia Li et al. MOLECULES
- Review of the Botanical Characteristics, Phytochemistry, and Pharmacology ofAstragalus membranaceus(Huangqi)
- (2014) Juan Fu et al. PHYTOTHERAPY RESEARCH
- HIF-1α Signaling Activation by Post-Ischemia Treatment with Astragaloside IV Attenuates Myocardial Ischemia-Reperfusion Injury
- (2014) Jingwen Si et al. PLoS One
- Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes
- (2013) Stephen C. Kolwicz et al. CIRCULATION RESEARCH
- Antitumor and immunomodulatory activity of Astragalus membranaceus polysaccharides in H22 tumor-bearing mice
- (2013) Bin Yang et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Extracts from Astragalus membranaceus limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia
- (2013) Xu Ma et al. JOURNAL OF ETHNOPHARMACOLOGY
- Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF-кB signaling pathway in isoproterenol-induced myocardial hypertrophy
- (2013) Juan Yang et al. JOURNAL OF ETHNOPHARMACOLOGY
- Astragaloside IV protects heart from ischemia and reperfusion injury via energy regulation mechanism
- (2013) Lei Tu et al. MICROCIRCULATION
- Synergistic Promotion of Blood Vessel Regeneration by Astragaloside IV and Ferulic Acid from Electrospun Fibrous Mats
- (2013) Huan Wang et al. MOLECULAR PHARMACEUTICS
- Astragaloside IV Protects against Cardiac Hypertrophy via Inhibiting the Ca2+/CaN Signaling Pathway
- (2013) Meili Lu et al. PLANTA MEDICA
- Flavonoid constituents and biological screening ofAstragalus bombycinusBoiss.
- (2012) Lamyaa F. Ibrahim et al. NATURAL PRODUCT RESEARCH
- Astragaloside IV Alleviates Hypoxia/Reoxygenation-Induced Neonatal Rat Cardiomyocyte Injury via the Protein Kinase A Pathway
- (2012) Da-Wei Zhang et al. PHARMACOLOGY
- Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy
- (2011) Ping Chen et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Astragaloside IV inhibits adenovirus replication and apoptosis in A549 cellsin vitro
- (2011) Lei Shang et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Astragaloside IV Improves Metabolic Syndrome and Endothelium Dysfunction in Fructose-Fed Rats
- (2011) Ning Zhang et al. MOLECULES
- Astragaloside IV Improves Homocysteine-Induced Acute Phase Endothelial Dysfunction via Antioxidation
- (2010) Li-Hong Qiu et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- ASTRAGALOSIDE IV ATTENUATES HYPOXIA-INDUCED CARDIOMYOCYTE DAMAGE IN RATS BY UPREGULATING SUPEROXIDE DISMUTASE-1 LEVELS
- (2009) Jiong-Yu Hu et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Astragaloside IV Improved Intracellular Calcium Handling in Hypoxia-Reoxygenated Cardiomyocytes via the Sarcoplasmic Reticulum Ca2+-ATPase
- (2008) Xiao-Le Xu et al. PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More